Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tiny molecules (hormones) are released from the bowels and other organs to the bloodstream in response to meals in order to orchestrate the metabolism. Oxyntomodulin, GLP-1 and glucagon are all known to regulate parameters such as appetite, food intake and induce weight loss.

Therefore we want to investigate mechanistic relations between the three hormones.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans

NCT00876213

Diabetes

COMPLETED

Separate and Combined Extrapancreatic Effects of the Incretin Hormones

NCT05177653

Pancreatectomy; Hyperglycemia

COMPLETED NA

GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose

NCT01079624

Physiology Gastroenterology Endocrinology

COMPLETED PHASE1

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

NCT04186026

Obesity

UNKNOWN NA

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

NCT01900340

Appetite and General Nutritional Disorders

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incretin Action Obesity

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy young males

GLP-1 infusion

Intervention Type OTHER

1 pmol/kg/min

Glucagon infusion

Intervention Type OTHER

3ng/kg/min

Oxyntomodulin infusion

Intervention Type OTHER

3 pmol/kg/min

GLP-1 and glucagon infusion

Intervention Type OTHER

1 pmol/kg/min 3 ng/kg/min

Placebo

Intervention Type OTHER

NaCl 9 g/L infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLP-1 infusion

1 pmol/kg/min

Intervention Type OTHER

Glucagon infusion

3ng/kg/min

Intervention Type OTHER

Oxyntomodulin infusion

3 pmol/kg/min

Intervention Type OTHER

GLP-1 and glucagon infusion

1 pmol/kg/min 3 ng/kg/min

Intervention Type OTHER

Placebo

NaCl 9 g/L infusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal fasting plasma glucose
* Normal glucose tolerance
* Normal haemoglobin levels
* Informed content

Exclusion Criteria

* Diabetes
* Pre diabetes (impaired glucose tolerance or impaired fasting glucose)
* 1st degree relatives with diabetes
* Obesity (BMI \> 30)
* Inflammatory bowels disease
* Bowels surgery
* Nephropathy
* Liver disease
* Medication which cannot be on hold for 24h

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes